GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NGL Fine-Chem Ltd (BOM:524774) » Definitions » Valuation Rank

NGL Fine-Chem (BOM:524774) Valuation Rank


View and export this data going back to 1995. Start your Free Trial

What is NGL Fine-Chem Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NGL Fine-Chem Valuation Rank Related Terms

Thank you for viewing the detailed overview of NGL Fine-Chem's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NGL Fine-Chem Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NGL Fine-Chem Ltd (BOM:524774) » Definitions » Valuation Rank
Comparable Companies
BOM:524280 BOM:507747 BOM:532815 NSE:SENORES LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568
Traded in Other Exchanges
NGLFINE:India
Address
301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
Website
https://www.nglfinechem.com
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. The company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. Its product includes Active Pharmaceutical Ingredients (APIs) animal health, APIs human health, Intermediates and Finished dosage form, of which maximum revenue is generated from Veterinary APIs. Its geographical segments include India, Europe, Asia Pacific, United States, and Rest of the world. The Group's business activities fall within a single business segment of pharmaceuticals.